Viz AAA

by Viz.ai  · Based in United States → — AI-powered disease detection and intelligent care coordination.
Emergency Medicine Radiology Vascular Surgery
Website
Claim this tool
Is this the maker? Claim the company →

Subscription model
Regulatory Status Disclosed

Overview

Viz AAA is an AI-powered solution developed by Viz.ai for the detection and triage of suspected Abdominal Aortic Aneurysm (AAA). It is the first FDA-cleared AI-powered solution specifically for this purpose. The tool utilizes artificial intelligence to automatically search for the presence of an abdominal aortic aneurysm from computed tomography angiography (CTA) scans from any scanner within a hospital network.

As part of the broader Viz™ AORTIC Module and the comprehensive Viz.ai One™ platform, Viz AAA integrates into existing hospital workflows, enabling care teams to quickly identify patients who may have a suspected AAA. This accelerated detection and triage are crucial for preventing catastrophic aortic emergencies, such as aortic rupture, by increasing the surveillance of these patients and facilitating faster treatment decisions. The platform also provides HIPAA-compliant communication tools to synchronize care across multidisciplinary teams, allowing for efficient collaboration and improved patient outcomes.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered automatic detection of suspected AAA from CTA scans
  • Automated triage and prioritization of cases
  • Integration into existing hospital workflows
  • Real-time alerts to care teams
  • HIPAA-compliant communication platform for multidisciplinary teams
  • Mobile access to high-fidelity imaging and patient information
  • Part of the Vizu2122 AORTIC Module for comprehensive aortic pathology solutions
  • Designed to accelerate treatment decisions and improve patient outcomes

Use Cases

  • Early detection of suspected Abdominal Aortic Aneurysms
  • Rapid triage of AAA cases to appropriate specialists
  • Prevention of catastrophic aortic emergencies like rupture
  • Increasing surveillance and follow-up for AAA patients
  • Streamlining care coordination for vascular conditions
  • Optimizing radiology workflow for incidental AAA findings

What Physicians Need to Know

ECG/EKG Analysis Capability
Viz HCM is an FDA-cleared AI algorithm that analyzes standard 12-lead ECGs to detect signs of hypertrophic cardiomyopathy (HCM), aiming for earlier identification of undiagnosed cases. Viz ACS consolidates ECGs from various sources (ambulance, ED, prior encounters) into a HIPAA-compliant mobile viewer for immediate access and serial change tracking.
Echocardiography AI Features
Viz.ai integrates FDA-cleared echocardiogram AI measurement and cardiac amyloidosis detection algorithms (via partnership with Us2.ai) to analyze new studies and flag suspected cases in real-time. It surfaces structured echo measurements powered by these FDA-cleared algorithms.
Cardiac CT/MRI Analysis
The Viz Cardio Suite includes dynamic viewers for CT and MRI images, allowing quick access and sharing of high-quality cardiac imaging. Through a partnership with Cleerly, Viz.ai incorporates FDA-approved software that uses coronary computed tomography angiography (CCTA) images with advanced AI to detect ischemia and stenosis, and to identify, quantify, and categorize plaque.
Heart Failure Risk Prediction
Viz Cardiac Amyloidosis supports earlier identification of suspected ATTR-CM (a cause of heart failure) from echocardiograms, integrating with EHR to provide heart failure-specific patient summaries. The platform aims to accelerate diagnosis and coordinated care for conditions like cardiac amyloidosis that lead to heart failure.
Coronary Artery Assessment
Viz.ai partners with Cleerly to integrate FDA-approved AI software that analyzes CCTA images to detect suspected coronary artery disease earlier, including identifying ischemia, stenosis, and quantifying/categorizing plaque.
Cardiac Monitoring Integration
Viz Connect is designed to increase cardiac monitoring referral volumes for cryptogenic stroke patients by connecting neurology and cardiology teams for earlier evaluation. Viz ACS consolidates ECGs from various points of care, aiding in continuous patient data review.
AHA/ACC Guideline Alignment
Viz.ai is a compatible vendor for the American Heart Association/American Stroke Association Get With The Guidelines registry, demonstrating alignment with research-based guidelines, particularly in stroke care. Its AI Care Pathway for cardiac amyloidosis guides clinicians through appropriate, guideline-based next steps. The platform also aligns with AHA guideline requirements for documentation and quantification in conditions like intracerebral hemorrhage. AI software for stroke detection was incorporated into AHA clinical guidelines in 2023 as standard of care.
Real-Time Alert Capability
Viz.ai One provides real-time AI-powered alerts to notify care teams of suspected diseases, ensuring timely intervention. Viz HCM flags suspected HCM cases from ECGs and triages them to specialists. Viz ACS facilitates real-time data sharing and team coordination to reduce false activations in acute coronary syndrome. Viz Assist, a suite of autonomous AI agents, delivers real-time clinical insights and coordinates actions across care teams.
Physician Tip

Viz.ai's platform can significantly accelerate diagnosis and treatment by leveraging AI to automatically detect suspected diseases from various imaging modalities (ECG, echo, CT/MRI) and integrate these insights into existing workflows. Physicians can benefit from real-time, HIPAA-compliant alerts and communication tools that connect multidisciplinary care teams, enabling faster decision-making and improved care coordination. The ability to access high-quality images and patient summaries on mobile devices streamlines workflow, reduces cognitive burden, and helps identify previously undiagnosed patients, ultimately leading to earlier interventions and better patient outcomes.

Viz.ai's platform, Viz.ai One, is designed for seamless integration with existing hospital systems, including Electronic Health Records (EHR) and Picture Archiving and Communication Systems (PACS). It also fosters strategic partnerships with other AI companies, such as Us2.ai for echocardiography analysis and Cleerly for coronary CT angiography (CCTA) plaque assessment, expanding its diagnostic capabilities. The platform's 'Viz Connect' feature facilitates communication and workflow across multidisciplinary specialists and care teams within and across institutions.

Details

Category Cardiology AI, Radiology & Imaging AI, Triage & ER/ICU AI
Pricing Subscription model
  • Annual fee based on the number of algorithms used and the size of the population served; no public pricing tiers available
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Viz AAA received U.S. Food and Drug Administration (FDA) 510(k) clearance (K223443) on March 21, 2023, as the first AI-powered solution for the detection and triage of suspected Abdominal Aortic Aneurysm.
Integrations
EHR Not specified
Specialties Emergency Medicine, Radiology, Vascular Surgery

What the Web Says

Viz AAA, developed by Viz.ai, is an AI-powered algorithm that has received FDA 510(k) clearance for the detection of suspected abdominal aortic aneurysms (AAA) using computed tomography angiography (CTA) scans. Physicians and healthcare professionals generally view Viz AAA as a powerful tool that can significantly improve the early identification and management of AAA, potentially preventing catastrophic events like aortic rupture. The platform aims to streamline workflows and accelerate treatment decisions by providing real-time insights and automated assessments.

Overall: Positive

Strengths

  • Earlier detection and treatment of AAA.
  • Automated AI assessments of CTA scans.
  • Ability to identify and refer patients at imminent risk of rupture.
  • High sensitivity (over 85%) and specificity (98.3%) in detecting AAA.
  • Integration into existing hospital workflows.
  • Improved care coordination and patient outcomes.

Limitations

  • No specific cons for Viz AAA were found in the provided search results.
  • General concerns about AI in healthcare, such as potential for bias or over-reliance, are not specifically attributed to Viz AAA in these reviews.

Based on reviews from: Viz.ai, Vascular News, Fierce Biotech, Reddit, Capterra, G2

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Viz AAA

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Vascular News
Viz.ai receives FDA 510(k) clearance for abdominal aortic aneurysm AI algorithm
Viz.ai received FDA 510(k) clearance for its Viz AAA algorithm, an AI-powered solution designed to detect and triage suspected abdominal aortic aneurysms (AAAs) from CT angiography scans. This algorithm is integrated into the Viz Aortic Module to accelerate treatment decisions and can help identify asymptomatic patients at risk of rupture.
2023-03
NS Medical Devices
Viz.ai receives FDA approval for AI algorithm to detect suspected AAA
Viz.ai's Viz AAA algorithm, the first FDA-cleared AI-powered solution for detecting and triaging suspected abdominal aortic aneurysms, uses AI to automatically search for AAAs in CT angiography scans. The company aims to prevent catastrophic aortic emergencies by increasing surveillance of these patients.
2023-03
DelveInsight
MedTech News | Viz.ai, BrainTale, NVIDIA, Median Technologies
Viz.ai announced on March 21, 2023, that it received FDA 510(k) clearance for its Viz AAA algorithm, making it the first FDA-cleared AI-powered solution for the detection and triage of suspected abdominal aortic aneurysms. The software integrates into existing hospital workflows to quickly identify patients with suspected AAAs.
2023-03
Diagnostic Imaging
New AI Algorithm for Abdominal Aortic Aneurysm Detection on CTA Gets FDA Nod
Viz AAA, an AI-enabled algorithm from Viz.ai, has received FDA 510(k) clearance for the detection of abdominal aortic aneurysms. This tool provides automated AI assessments of CT angiography to facilitate earlier detection and treatment for patients with AAAs.
2023-03
Fierce Biotech
Viz.ai snags FDA nod for AI to spot abdominal aortic aneurysms in chest scans
Viz.ai has secured FDA clearance for its Viz AAA algorithm, which uses AI to detect abdominal aortic aneurysms in CT angiography scans. This algorithm is integrated into the Viz Aortic module to help prevent catastrophic aortic emergencies.
2023-03
Applied Radiology
Viz.ai Nets FDA Clearance for AAA AI Algorithm | Applied Radiology
Viz.ai announced FDA clearance for its Viz AAA algorithm, an AI tool that automatically searches for abdominal aortic aneurysms in CT angiography scans. This solution aims to improve early detection and referral for patients at risk of rupture.
2023-03
Applied Radiology
AI Software Enhances Detection of Abdominal Aortic Aneurysms on CT Scans
A retrospective study presented at the ARRS 2025 Annual Meeting evaluated Viz AAA, an AI-powered software, demonstrating 87.4% sensitivity and 94.1% specificity in detecting incidental AAAs on CECT scans. The study suggests that integrating Viz AAA into radiological workflows could enhance timely detection and management.
2025-05
PMC - NIH
Artificial Intelligence-Based Predictive Modeling for Aortic Aneurysms
A review article highlights Viz AAA as an innovative AI-powered tool that automates CT angiography assessment for timely AAA detection, enhancing early intervention strategies. This contributes to the revolutionizing of AAA management through deep learning techniques.
2025-02

Videos

Product demos, reviews, and walkthroughs for Viz AAA.

View all on YouTube

Frequently Asked Questions

Viz AAA automatically analyzes CT angiography (CTA) scans from any scanner in your hospital network for suspected AAAs. If a potential aneurysm is detected, it automatically alerts and displays high-fidelity patient scans on providers' mobile devices, facilitating rapid communication and care coordination among specialists.
Yes, Viz AAA is the first FDA-cleared AI-powered solution for the detection and triage of suspected abdominal aortic aneurysms. Viz.ai emphasizes HIPAA-compliant communication within its platform and has passed SOC 2 Type II + HIPAA audits, ensuring secure handling of patient information.
While studies show high sensitivity and specificity (e.g., 87.4% sensitivity, 94.1% specificity), one retrospective study noted the AI failed to analyze 10 cases, including four where AAAs were present. This suggests that while highly effective, continuous monitoring and physician oversight remain crucial, as with any AI tool.
While Viz AAA is noted as the first FDA-cleared AI solution specifically for AAA detection and triage, other AI solutions exist for broader vascular pathologies or medical image analysis, such as Aidoc and Blackford. Viz.ai's platform differentiates itself by integrating detection with intelligent care coordination across multiple vascular conditions.
Specific pricing models for Viz AAA are typically not publicly disclosed and often depend on the size of the institution, the scope of implementation, and the specific modules integrated. Viz.ai generally operates on an enterprise subscription model for hospitals and health systems. Interested health systems usually need to contact Viz.ai directly for a customized quote.
Real-world studies indicate that Viz AAA can significantly improve the speed of diagnosis and care, leading to earlier detection, improved surveillance, and more thoughtful interventional planning. This can ultimately help prevent catastrophic aortic emergencies and improve patient outcomes by accelerating time to treatment.
Viz.ai offers clinical specialists to customize the app based on existing workflows and provides clinician-led product training and educational content through Viz Academy. The goal is to integrate the software seamlessly into hospital workflows, enabling physicians to quickly identify suspected AAAs and coordinate care efficiently.

Compare Viz AAA

VS
Viz AAA vs EchoNext
Cardiology AI Adjacent · 65/100
Viz AAA and EchoNext are both FDA-cleared AI tools focused on cardiovascular health, but they address different diagnostic needs. Viz AAA specializes in the detection and triage of…
VS
Tempus ECG-Low EF vs Viz AAA
Cardiology AI Adjacent · 65/100
Tempus ECG-Low EF and Viz AAA are both FDA-cleared AI tools in cardiology, but they address different conditions and utilize distinct data sources. Tempus ECG-Low EF analyzes ECGs…
VS
LINQ II Insertable Cardiac Monitor vs Viz AAA
Cardiology AI Adjacent · 60/100
While both tools leverage AI in cardiology, they address different stages of patient care and distinct cardiac conditions. Medtronic LINQ II focuses on long-term, continuous heart rhythm monitoring…
VS
Viz AAA vs OMRON VitalSight
Cardiology AI Adjacent · 60/100
Viz AAA is an AI-powered solution focused on the rapid detection and triage of acute conditions like Abdominal Aortic Aneurysm from CT scans, aiming to accelerate diagnosis and…

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

More from Viz.ai

ContaCT
Viz.AI
Neurology AI
Viz.ai is a pioneering AI-powered care coordination platform that accelerates disease detection and streamlines clinical workflows. With multiple FDA clearances, including the initial Viz.AI Contact application for stroke, it helps ensure patients receive timely treatment across over 1,700 hospitals globally.
Subscription-based
Viz ANEURYSM
Viz.ai
Neurology AI
Viz ANEURYSM is an FDA-cleared AI-powered solution by Viz.ai that auto-detects suspected cerebral aneurysms in CT angiograms (CTAs), streamlining neurovascular care coordination and facilitating timely patient management.
Contact for pricing
Viz CTP
Viz.ai
Clinical Decision Support & Reference
Viz.ai is a pioneer in AI-powered disease detection and intelligent care coordination, leveraging over 50 FDA-cleared algorithms to analyze medical imaging and streamline clinical workflows for faster diagnosis and treatment.
Subscription model
Viz HCM
Viz.ai
Cardiology AI
Viz HCM is an FDA-cleared AI tool by Viz.ai that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM) and coordinate cardiac care, significantly reducing diagnosis time.
Subscription-based

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19

Investors who backed Viz AAA

Funded through the company that built this tool.

Scale Venture Partners
VC T3
Foster City, United States
$5M-$25M
Scale Venture Partners is a Foster City-based growth-stage software firm investing primarily in B2B SaaS, with a long track record of leading…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
AI Tool Finder
AI-powered search. Results may not be comprehensive.